Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis-Reference-Cited by-同舟云学术

Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis

Published:2022-02-28 Issue:6 Volume:29 Page:1708-1718
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Euro J of Neurology

Author:

Mariottini Alice¹²^ORCID,Bulgarini Giovanni¹,Forci Benedetta¹,Innocenti Chiara³,Mealli Fabrizia⁴⁵,Mattei Alessandra⁴⁵,Ceccarelli Chiara⁴,Repice Anna Maria²,Barilaro Alessandro²,Mechi Claudia²,Saccardi Riccardo³,Massacesi Luca¹²

Affiliation:

1. Department of Neurosciences, Drug and Child Health University of Florence Florence Italy

2. Department of Neurology 2 and Tuscan Region MS Referral Centre Careggi University Hospital Florence Italy

3. Cell Therapy and Transfusion Medicine Unit Careggi University Hospital Florence Italy

4. Department of Statistics Computer Science Applications “Giuseppe Parenti” University of Florence Florence Italy

5. Florence Centre for Data Science Florence Italy

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.15280

Reference38 articles.

1. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis

2. Delaying the inevitable: Are disease modifying drugs for progressive MS worthwhile?

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects;Pharmacological Reports;2024-08-23

2. Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic review;European Journal of Neurology;2024-08-05

3. Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-08

4. Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis;Journal of Neurology, Neurosurgery & Psychiatry;2024-03-27

5. Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation;Autoimmunity Reviews;2024-02